Keros Therapeutics (KROS) Cash & Equivalents (2019 - 2025)
Historic Cash & Equivalents for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $693.5 million.
- Keros Therapeutics' Cash & Equivalents rose 3067.51% to $693.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $693.5 million, marking a year-over-year increase of 3067.51%. This contributed to the annual value of $559.9 million for FY2024, which is 6908.84% up from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' Cash & Equivalents is $693.5 million, which was up 3067.51% from $690.2 million recorded in Q2 2025.
- Over the past 5 years, Keros Therapeutics' Cash & Equivalents peaked at $720.5 million during Q1 2025, and registered a low of $215.6 million during Q2 2022.
- Its 5-year average for Cash & Equivalents is $381.2 million, with a median of $322.0 million in 2023.
- The largest annual percentage gain for Keros Therapeutics' Cash & Equivalents in the last 5 years was 36810.78% (2021), contrasted with its biggest fall of 1347.77% (2021).
- Keros Therapeutics' Cash & Equivalents (Quarter) stood at $230.0 million in 2021, then increased by 21.3% to $279.0 million in 2022, then increased by 18.67% to $331.1 million in 2023, then soared by 69.09% to $559.9 million in 2024, then increased by 23.85% to $693.5 million in 2025.
- Its Cash & Equivalents was $693.5 million in Q3 2025, compared to $690.2 million in Q2 2025 and $720.5 million in Q1 2025.